Colon Cancer

P=N/A, N=15, Completed, University of Illinois at Chicago | N=44 --> 15 | Enrolling by invitation --> Completed

P2, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended

P2, N=88, Not yet recruiting, Korea University Anam Hospital

Tragically, the patient experienced respiratory decompensation and passed away 10 weeks after the treatment. This case underscores the potential of FAP-targeted radioligand therapy in managing advanced colon cancer and suggests that earlier intervention might be beneficial.

Density functional theoretical (DFT) studies at the TD-SCF/B3LYP/3-21G level support the proposed N1-p-NPP interaction and provide insights into the optimized geometries and associated electronic (HOMO-LUMO) properties. This work bridges catalytic chemistry and cancer biology, positioning the azo-uracil derived Ni(ii) complex as an emerging multifunctional therapeutic candidate.

These findings reveal the dual oncogenic function of NSUN2 in COAD-it not only propels tumor progression through direct signaling activation but also enables immune evasion by attenuating anti-tumor immunity. In summary, this study systematically clarifies how NSUN2 promotes COAD development by simultaneously activating the Wnt/β-catenin pathway and suppressing CD8+ T-cell-mediated immunity, providing a strong mechanistic foundation for its potential as a therapeutic target in future COAD treatment strategies.

Consistently, single-cell analysis of colorectal tumors shows PUM1 positively correlates with PD-L1 and inversely with CD8+ T cell infiltration. Together, our study defines a novel IFN-γ-responsive post-transcriptional regulation that controls PD-L1 expression and tumor immune suppression.

Compound 2c exhibited potent activity against the colon cancer cell line HCT116 with an IC₅₀ of 5.17 ± 0.48 μM and a selectivity index (SI) of ≈3.42, outperforming the positive control doxorubicin (DOX, SI ≈ 2.19)...In a mouse colon cancer graft model, compound 2c achieved a 49.70% tumor inhibition rate at a dose of 20 mg/kg, with no obvious abnormalities observed in major organs. In conclusion, 2c is an effective mitochondrial MTHFD2 inhibitor with potential to develop into a potent anti-colon cancer drug.

Given the advanced dMMR status of the primary lesion, neoadjuvant immunotherapy with pembrolizumab was administered, resulting in marked radiologic tumor regression...This case represents a rare intra-patient demonstration of dMMR status, together with a CD8-rich tumor microenvironment, conferring considerable sensitivity to ICI therapy, and pMMR status exhibiting resistance, despite identical systemic immune exposure. Our findings suggest that MMR status may serve as a clinically relevant biomarker for response to neoadjuvant immunotherapy in CRC and highlight the importance of independent biomarker assessment for each synchronous tumor.

Ferula assa-foetida shows potent anti-cancer effects against HCT-116 cells, with PD-L1 suppression suggesting immunotherapy synergy. Further in vivo and clinical studies are needed to confirm its therapeutic role in CRC.

Either the depletion of aHSCs or pharmacological inhibition of the PGE2-synthesizing enzyme Cyclooxygenase-2 (COX-2) with Celecoxib (CLX) restored NK cell function and suppressed LM. Notably, CLX treatment synergized with anti-NKG2A-based immunotherapy, significantly boosting its efficacy against LM in the fibrotic liver. Our findings unveil a critical "aHSC-PGE2-NK cell" axis in liver fibrosis-induced immunosuppression and provide a compelling therapeutic strategy for the clinical management of LM.

P1, N=40, Recruiting, University of Minnesota | Trial primary completion date: Apr 2026 --> Sep 2026